MED'INN'PHARMA
keyboard_backspaceBack to Home
Contact
4 Rue Charles Bried - BioInnovation bldg - 2nd floor, room#6
25000 BESANCON
France
Dirigeant
About us
Med’Inn’Pharma (MIP) is a pre-clinical stage Biotech with the mission to develop a new generation of human cell-derived therapeutics, based on secretomes, with truly disease modifying properties to tackle inflammatory and degenerative diseases at their root, providing better solutions for longer lives in good health
Business offer
Med’Inn’Pharma (MIP) offers a technological platform allowing the production of secretomes produced by human cells sourced from blood, tissues or stem cells, and the transformation of these secretomes into biological medicines 100% of human origin.
This platform allows MIP to offer two drug candidates with pro-resolving properties in order to control inflammation by re-engaging the inflammation resolution program. These candidates will soon be evaluated in the rare disease Systemic sclerosis and in rheumatoid arthritis for patients refractory to biotherapies.
Activities
- Therapeutic Product
- Nervous Central System
- Immunology
- Inflammation
- Bioproduction
- Batches production type
- Mammalian
- Pilot Batches
- Tests
- Optimization
- Scale-Up process
- Process optimization & validation
- Volume
- Preclinical / Tox
- Low volume (< 200 L)
- DSP (Recovery)
- Harvest
- Filtration
- Purification
- Cell origin
- Single donor
- Pool of donors
- Cell Banking
- IPs
- MSC
- Apheresis
- Bioproduction engineering
- Cell Expansion
- Cell factory
- Purification/Extraction
- Filtration / microfiltration / ultrafiltration
- Centrifugation
